ReviewJournal of gastric cancer2026
Gastric Cancer Organoids: Mechanistic Insights, Drug Discovery, and Translational Advances in Precision Medicine.
Review in Journal of gastric cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Significant advances in the treatment of localized gastric cancer have been achieved through early screening, improved diagnostic techniques, surgeries, and adjuvant chemotherapy; however, the need for personalized treatment remains under debate. This review highlights the use of gastric cancer organoid (GCO) models to study cancer mechanisms, drug discovery, and precision medicine, focusing on their ability to simulate the tumor microenvironment, reveal cell heterogeneity, and assess drug responses. In particular, the integration of CRISPR/Cas9 gene editing with GCOs provides a powerful platforms for identifying new drug targets and supporting clinical applications in precision medicine. This review also explores the potential of these organoids in future research, particularly in optimizing treatment strategies and developing personalized therapies, thus offering new directions for precision treatment of gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.